AU Patent

AU2014232714B2 — Metabolites of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide

Assigned to Exelixis Inc · Expires 2018-07-19 · 8y expired

What this patent protects

The invention relates to metabolites of cabozantinib (I) as well as uses thereof.

USPTO Abstract

The invention relates to metabolites of cabozantinib (I) as well as uses thereof.

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: AU2014232714B2
Jurisdiction: AU
Classification: —
Expires: 2018-07-19
Drug substance claim: No
Drug product claim: No
Assignee: Exelixis Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.